Results 261 to 270 of about 2,636,203 (317)

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MI

ESC Heart Failure, EarlyView.
Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti, Javed Butler, Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Johann Bauersachs, Antoni Bayes‐Genis, Shaun G. Goodman, Tomasz Gasior, James L. Januzzi, Renato D. Lopes, Piotr Ponikowski, Xavier Rossello, Morten Schou, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, Stefan D. Anker   +23 more
wiley   +1 more source

In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial. [PDF]

Eur Heart J
Tanaka A, Kida K, Matsue Y, Imai T, Suwa S, Taguchi I, Hisauchi I, Teragawa H, Yazaki Y, Moroi M, Ohashi K, Nagatomo D, Kubota T, Ijichi T, Ikari Y, Yonezu K, Takahashi N, Toyoda S, Toshida T, Suzuki H, Minamino T, Nogi K, Shiina K, Horiuchi Y, Tanabe K, Hachinohe D, Kiuchi S, Kusunose K, Shimabukuro M, Node K.   +29 more
europepmc   +1 more source

Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL‐HF

ESC Heart Failure, EarlyView.
Abstract Aims The EMAIL‐HF trial aims to evaluate whether a digital guideline implementation strategy can increase and accelerate initiation of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and results EMAIL‐HF is a pragmatic, registry‐based, randomized controlled trial including patients with a ...
Mariam Elmegaard, Lars Køber, Mads Kristian Ersbøll, Theis Lange, Christian Ditlev Tuxen, Mette Rauhe Mouridsen, Trine Kiilerich Lauridsen, Jens Jakob Thune, Peter Godsk Jørgensen, Morten Lamberts, Nadia Paarup Dridi, Peter Bonfils, Morten Petersen, Nis Ottesen Stride, Anders Barasa, Jesper Jensen, Caroline Garred, Emil Fosbøl, Emil Wolsk, John McMurray, Mark Petrie, Morten Schou   +21 more
wiley   +1 more source

Interrogation of Interfering Factors in ELISA Detecting Angiotensin Receptor Antibodies and Specificity Validation Using the Adsorption Elution Crossmatch (AXE) Technique. [PDF]

HLA
Karamafrooz A, Nguyen J, Ma H, Lowe D, Trinh M, Pei R, Carroll R.   +6 more
europepmc   +1 more source

A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting

ESC Heart Failure, EarlyView.
Abstract Aims There is growing recognition of the burden and prognostic significance of WHF treated in the outpatient setting. However, there is currently a lack of prospective real‐world data in this area of HF care. This study aims to analyse the natural history of outpatient WHF.
Joseph McCambridge, Fiyinfoluwa Fabamwo, Shadia Taha, Dermot McCaffrey, Matthew Barrett, Ciara Mahon, Kenneth McDonald   +6 more
wiley   +1 more source

Angiotensin receptor-neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction. [PDF]

ESC Heart Fail
Cho DH, Choi J, Youn JC, Kim MN, Lee CJ, Son JW, Yoo BS.   +6 more
europepmc   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Epidemiology, pathophysiology, diagnosis and management of atrial functional mitral regurgitation: An expert opinion paper

ESC Heart Failure, EarlyView.
The graphical abstract summarizes the key features of AFMR in terms of epidemiology, pathophysiology, diagnosis, medical therapy and rhythm control, surgical and transcatheter interventions, and future directions. Created in BioRender (https://BioRender.com/3zj03ko).
Matteo Pagnesi, Mauro Riccardi, Francesco Maisano, Julia Grapsa, Vassilis Barberis, Magdy Abdelhamid, Elena‐Laura Antohi, Henrike Arfsten, Nicole Karam, Denisa Muraru, Karl‐Philipp Rommel, Anna Sannino, Wilfried Mullens, Marianna Adamo, Marco Metra   +14 more
wiley   +1 more source

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

ESC Heart Failure, EarlyView.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori, Sergio Davinelli, Armando Ferrera, Alessandro Medoro, Carlo Barsali, Allegra Battistoni, Maurizio Volterrani, Massimo Volpe, Luciano Saso, Speranza Rubattu   +9 more
wiley   +1 more source

Potential renoprotective effects and possible underlying mechanisms of angiotensin receptor-neprilysin inhibitors in cardiorenal syndrome. [PDF]

Front Med (Lausanne)
Rahman MM, Rahman A, Nishiyama A.
europepmc   +1 more source